Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.001 par value
Symbol
VYGR on Nasdaq
Shares outstanding
55,482,166
Price per share
$3.93
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
30,211,020
Total reported value
$141,111,218
% of total 13F portfolios
0%
Share change
-3,000,957
Value change
-$12,466,237
Number of holders
114
Price from insider filings
$3.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARMISTICE CAPITAL, LLC 7.6% -23% $19,614,000 -$5,772,120 4,200,000 -23% Armistice Capital, LLC 30 Sep 2025
EcoR1 Capital, LLC 6.8% $18,696,980 4,003,636 EcoR1 Capital, LLC 30 Sep 2025
BlackRock, Inc. 6.4% $12,445,128 3,525,532 BlackRock, Inc. 31 Mar 2025

As of 30 Sep 2025, 114 institutional investors reported holding 30,211,020 shares of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR). This represents 54% of the company’s total 55,482,166 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 10% 5,607,271 -2.2% 0% $26,185,956
ARMISTICE CAPITAL, LLC 7.6% 4,200,000 -12% 0.62% $19,614,000
VANGUARD GROUP INC 5.9% 3,250,066 +1.3% 0% $15,177,809
MILLENNIUM MANAGEMENT LLC 4.1% 2,292,703 +154% 0.01% $10,706,923
Vestal Point Capital, LP 2.7% 1,475,000 0% 0.31% $6,888,250
DIMENSIONAL FUND ADVISORS LP 2.3% 1,283,156 -9.7% 0% $5,992,508
GEODE CAPITAL MANAGEMENT, LLC 2.1% 1,148,612 +2.8% 0% $5,364,995
Erste Asset Management GmbH 2% 1,116,793 0% 0.05% $5,260,095
STATE STREET CORP 1.7% 925,358 +3.5% 0% $4,321,422
EcoR1 Capital, LLC 1.2% 670,303 -83% 0.15% $3,130,315
MORGAN STANLEY 1.1% 599,688 +6.4% 0% $2,800,543
PRICE T ROWE ASSOCIATES INC /MD/ 1% 581,699 -4.8% 0% $2,718,000
UBS Group AG 0.85% 473,100 +3.9% 0% $2,209,378
BANK OF AMERICA CORP /DE/ 0.77% 427,430 -26% 0% $1,996,099
CITADEL ADVISORS LLC 0.72% 398,226 +105% 0% $1,859,715
NORTHERN TRUST CORP 0.71% 394,751 -2.4% 0% $1,843,488
Fiduciary Trust Co 0.6% 334,397 +29% 0.02% $1,561,634
GOLDMAN SACHS GROUP INC 0.54% 297,573 +5.9% 0% $1,389,666
RENAISSANCE TECHNOLOGIES LLC 0.47% 262,450 -33% 0% $1,225,642
ROYAL BANK OF CANADA 0.44% 242,672 -16% 0% $1,133,000
JPMORGAN CHASE & CO 0.39% 217,411 -1.3% 0% $1,015,310
SPHERA FUNDS MANAGEMENT LTD. 0.36% 199,761 0.22% $932,884
Bank of New York Mellon Corp 0.35% 193,415 +2.5% 0% $903,248
GSA CAPITAL PARTNERS LLP 0.33% 184,203 -18% 0.07% $860,000
AQR CAPITAL MANAGEMENT LLC 0.32% 176,216 -38% 0% $822,928

Institutional Holders of Voyager Therapeutics, Inc. - Common Stock, $0.001 par value (VYGR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 139,979 $555,904 +$112,908 $3.93 8
2025 Q3 30,211,020 $141,111,218 -$12,466,237 $4.67 114
2025 Q2 33,174,673 $103,118,305 -$5,022,778 $3.11 107
2025 Q1 34,693,910 $117,319,204 -$2,380,756 $3.38 114
2024 Q4 34,577,603 $195,996,497 -$3,226,096 $5.67 130
2024 Q3 35,034,671 $205,128,146 -$20,241,650 $5.85 126
2024 Q2 38,132,801 $301,619,686 +$18,919,346 $7.91 126
2024 Q1 35,559,200 $331,104,508 +$80,441,114 $9.31 132
2023 Q4 26,951,934 $227,544,384 -$3,558,359 $8.44 107
2023 Q3 27,251,321 $211,188,846 +$537,246 $7.75 111
2023 Q2 26,875,646 $307,720,979 +$48,627,840 $11.45 106
2023 Q1 23,842,811 $183,821,375 -$454,983 $7.71 82
2022 Q4 23,994,562 $146,245,078 -$700,357 $6.10 69
2022 Q3 24,135,758 $142,907,865 +$347,568 $5.92 67
2022 Q2 24,076,804 $142,325,318 +$7,681,335 $5.91 74
2022 Q1 22,468,342 $171,312,566 +$28,627,560 $7.62 67
2021 Q4 18,846,543 $51,240,128 -$8,744,189 $2.71 52
2021 Q3 22,241,759 $58,623,539 -$4,030,195 $2.63 63
2021 Q2 23,442,885 $96,817,913 -$15,060,885 $4.13 72
2021 Q1 26,694,047 $125,738,812 -$5,939,201 $4.71 94
2020 Q4 27,690,758 $198,031,668 -$6,797,504 $7.15 95
2020 Q3 28,071,762 $299,694,014 -$21,155,353 $10.67 107
2020 Q2 29,835,329 $376,668,426 -$3,115,117 $12.62 108
2020 Q1 30,273,841 $276,907,152 -$8,724,603 $9.15 116
2019 Q4 30,853,647 $429,835,458 -$4,780,916 $13.95 134
2019 Q3 30,673,858 $527,882,858 +$3,530,435 $17.21 129
2019 Q2 29,288,476 $796,370,599 +$141,852,717 $27.22 124
2019 Q1 27,472,078 $525,823,405 +$8,007,882 $19.14 110
2018 Q4 27,858,099 $261,831,496 -$17,131,000 $9.40 114
2018 Q3 28,912,415 $547,055,271 -$4,047,273 $18.92 117
2018 Q2 29,099,816 $568,637,489 +$41,402,106 $19.54 124
2018 Q1 27,065,667 $508,508,214 +$36,985,561 $18.79 107
2017 Q4 25,186,321 $418,085,441 +$68,360,039 $16.60 98
2017 Q3 11,312,957 $232,911,475 +$24,126,972 $20.59 74
2017 Q2 10,949,052 $98,104,354 -$1,702,259 $8.96 52
2017 Q1 11,060,819 $146,442,646 +$8,714,480 $13.24 46
2016 Q4 10,954,007 $139,545,784 +$4,079,335 $12.74 55
2016 Q3 10,637,831 $127,760,820 +$781,532 $12.01 50
2016 Q2 10,598,201 $116,470,479 +$5,910,371 $10.99 48
2016 Q1 10,015,808 $86,972,821 -$3,380,554 $8.73 41
2015 Q4 10,403,150 $225,137,498 +$219,950,498 $21.90 35